Trial Profile
Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Antineoplastics; Antithymocyte globulin; Busulfan; Cyclophosphamide; Fludarabine; Immunosuppressants; Mycophenolate mofetil; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 28 May 2014 Status changed from active, no longer recruiting to completed.
- 09 May 2014 Primary endpoint 'Acute-graft-versus-host-disease' has not been met.
- 09 May 2014 Results published in the Lancet Oncology.